Division of Child Neurology, Faculty of Medicine, Mardin Artuklu University, Mardin, Turkey.
Faculty of Medicine, Fırat University, Elazıg, Turkey.
Clin Pediatr (Phila). 2024 Jun;63(6):798-804. doi: 10.1177/00099228231194411. Epub 2023 Aug 18.
There is still no evidence-based guideline and consensus on the treatment Sydenham's Chorea (SC). The first-line medication preference of specialists depends on personal experience and is variable. In this study, we evaluate the treatment results of pediatric patients who were treated with valproic acid (VPA). The medical records of 17 patients diagnosed with SC were reviewed retrospectively. The mean time to clinical improvement was found as approximately 5 days, the mean duration of remission as 13.60 ± 3.94 weeks and the mean duration of medication use was found as 17.96 ± 3.81 weeks. No side effects were observed in any of the patients and relapse occurred in 2 patients. A positive correlation was found between the initial C-reactive protein (CRP) level and the duration of medication use. Until evidence-based guidelines are established, VPA can be used as an effective, safe, and inexpensive first-line treatment option, especially in pediatric patients.
目前,对于抽动秽语综合征(Sydenham's Chorea,SC)的治疗尚无循证医学指南和共识。专家的一线药物选择取决于个人经验,存在差异。本研究评估了使用丙戊酸(valproic acid,VPA)治疗的儿科患者的治疗结果。我们回顾性分析了 17 例确诊为 SC 的患者的病历。临床改善的平均时间约为 5 天,缓解的平均持续时间为 13.60±3.94 周,药物使用的平均持续时间为 17.96±3.81 周。所有患者均未观察到不良反应,2 例患者复发。初始 C 反应蛋白(C-reactive protein,CRP)水平与药物使用时间呈正相关。在建立循证医学指南之前,VPA 可作为一种有效、安全且廉价的一线治疗选择,特别是在儿科患者中。